Current status of conditioning regimens in haploidentical hematopoietic cell transplantation

Figures & data

Table 1. Selected studies of PTCY-based Haplo-HCT using MAC.

Study	N	Study type	Median age (range), years	Disease	Conditioning regimen	NRM	Relapse	OS
Solomon et al. [26]	20	Prospective	44 (25–56)	Various	FLU/BU/CY	10% at 1 year	40% at 1 year	69% at 1 year
Solomon et al. [27]	82	Retrospective	42 (19–61)	Various	FLU/TBI	13% at 4 years	27% at 4 years	67% at 4 years
Chiusolo et al. [44]	150	Retrospective	51 (17–74)	AML	FLU/TBI or TBF	20% at 4 years	24% at 4 years	57% at 4 years
Sugita et al. [39]	50	Prospective	36 (17–60)	Various	FLU/TBI or FLU/BU/TBI	10% at 2 years	36% at 2 years	68% at 2 years
Symons et al. [45]	96	Prospective	42 (1–65)	Various	CY/TBI or BU/CY	11% at 3 years	43% at 3 years	54% at 3 years
Cieri et al. [46]	40	Retrospective	55 (21–78)	Various	FLU/MEL/TREO	17% at 1 year	35% at 1 year	56% at 1 year
Dholaria et al. [47]	919	Retrospective	47 (18–78)	AML	Chemotherapy-based	24% at 2 years	28% at 2 years	55% at 2 years
Dholaria et al. [47]	89	Retrospective	38 (19–65)	AML	TBI-based	21% at 2 years	34% at 2 years	50% at 2 years
Dholaria et al. [48]	239	Retrospective	32 (18–65)	ALL	Chemotherapy-based	31% at 2 years	32% at 2 years	47% at 2 years
Dholaria et al. [48]	188	Retrospective	32 (18–68)	ALL	TBI-based	21% at 2 years	34% at 2 years	51% at 2 years
Swoboda et al. [49]	117	Retrospective	31 (18–60)	ALL	FLU/TBI	20% at 2 years	35% at 2 years	54% at 2 years
Swoboda et al. [49]	119	Retrospective	36 (19–62)	ALL	TBF	31% at 2 years	27% at 2 years	53% at 2 years

ALL: acute lymphoblastic leukemia; AML; acute myeloid leukemia; BU: busulfan; CY: cyclophosphamide; FLU: fludarabine; Haplo-HCT: haploidentical related hematopoietic cell transplantation; MAC; myeloablative conditioning; MEL: melphalan; NRM: non-relapse mortality; OS: overall survival; PTCY: posttransplant cyclophosphamide; TBF: thiotepa/busulfan/fludarabine; TBI: total body irradiation; TREO: treosulfan

Table 2. Selected studies of PTCY-based Haplo-HCT using RIC.

Study	N	Study type	Median age (range), years	Disease	Conditioning regimen	NRM	Relapse	OS
Luznik et al. [12]	68	Prospective	46 (1–71)	Various	FLU/CY/TBI	15% at 1 year	51% at 2 years	36% at 2 years
Burroughs et al. [53]	28	Retrospective	32 (14–62)	HL	FLU/CY/TBI	9% at 2 years	40% at 2 years	58% at 2 years
Kasamon et al. [54]	271	Retrospective	61 (50–75)	Various	FLU/CY/TBI	12% at 1 year	46% at 3 years	46% at 3 years
Brammer et al. [55]	22	Retrospective	46 (20–62)	Lymphoma	FLU/MEL + TT or TBI	19% at 1 year	27% at 2 years	54% at 2 years
Ciurea et al. [56]	43	Retrospective	61 (55–69)	AML, MDS	FLU/MEL + TT or TBI	34% at 2 years	24% at 2 years	42% at 2 years
Sugita et al. [39]	77	Prospective	58 (22–65)	Various	FLU/BU/TBI	20% at 2 years	45% at 2 years	44% at 2 years
Castagna et al. [57]	47	Prospective	43 (20–68)	Lymphoma	FLU/CY/TT + TBI or TMLI	15% at 4 year	28% at 4 years	64% at 4 years
Tanaka et al. [58]	18	Prospective	59 (27–64)	ATLL	FLU/MEL/TBI	11% at 1 year	28% at 1 year	73% at 2 years
Devillier et al. [59]	97	Retrospective	52 (43–57)*	AML	FLU/CY/TBI	16% at 2 years	43% at 2 years	51% at 2 years
Devillier et al. [59]	106	Retrospective	53 (44–57)*	AML	TBF	22% at 2 years	15% at 2 years	63% at 2 years
Devillier et al. [59]	117	Retrospective	68 (66–70)*	AML	FLU/CY/TBI	23% at 2 years	28% at 2 years	55% at 2 years
Devillier et al. [59]	170	Retrospective	65 (63–68)*	AML	TBF	30% at 2 years	22% at 2 years	54% at 2 years
Al Malki et al. [60]	31	Prospective	37 (21–58)	Various	FLU/CY/TMLI	9% at 1 year	17% at 1 year	83% at 1 year

*Interquartile range.

AML; acute myeloid leukemia; ATLL: adult T-cell leukemia/lymphoma; BU: busulfan; CY: cyclophosphamide; FLU: fludarabine; Haplo-HCT: haploidentical related hematopoietic cell transplantation; HL: Hodgkin lymphoma; MDS: myelodysplastic syndrome; MEL: melphalan; NRM: non-relapse mortality; OS: overall survival; PTCY: posttransplant cyclophosphamide; RIC: reduced-intensity conditioning; TBF: thiotepa/busulfan/fludarabine; TBI: total body irradiation; TMLI: total marrow and lymphoid irradiation; TT: thiotepa

Table 3. Selected studies of PTCY-based Haplo-HCT comparing MAC and RIC.

Study	N	Study type	Median age (range), years	Disease	Conditioning regimen	NRM	Relapse	OS
Huselton et al. [71]	61	Retrospective	48 (19–70)	Various	MAC	39% at 1 year	21% at 1 year	51% at 1 years
Huselton et al. [71]	87	Retrospective	55 (19–73)	Various	RIC	27% at 1 year	37% at 1 year	43% at 1 years
Modi et al. [72]	24	Retrospective	47 (21–78)	Various	MAC	22% at 1 years	22% at 1 year	69% at 1 year
Modi et al. [72]	65	Retrospective	62 (22–78)	Various	RIC	22% at 1 years	18% at 1 year	67% at 1 year
Solomon et al. [73]	381	Retrospective	NA (18–54)	AML, ALL, MDS	MAC	18% at 3 years	38% at 3 years	54% at 3 years
Solomon et al. [73]	308	Retrospective	NA (18–54)	AML, ALL, MDS	RIC	17% at 3 years	51% at 3 years	49% at 3 years
Solomon et al. [73]	145	Retrospective	NA (55–70)	AML, ALL, MDS	MAC	30% at 3 years	34% at 3 years	42% at 3 years
Solomon et al. [73]	491	Retrospective	NA (55–70)	AML, ALL, MDS	RIC	24% at 3 years	46% at 3 years	38% at 3 years
Santoro et al. [74]	373	Retrospective	55 (45–79)	AML	MAC	31% at 2 years	25% at 2 years	48% at 2 years
Santoro et al. [74]	539	Retrospective	61 (45–76)	AML	RIC	30% at 2 years	29% at 2 years	44% at 2 years

ALL: acute lymphoblastic leukemia; AML; acute myeloid leukemia; Haplo-HCT: haploidentical related hematopoietic cell transplantation; MAC; myeloablative conditioning; MDS: myelodysplastic syndrome; NA: not available; NRM: non-relapse mortality; OS: overall survival; PTCY: posttransplant cyclophosphamide; RIC: reduced-intensity conditioning.

Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18(12):1859–1866. doi:10.1016/j.bbmt.2012.06.019

 PubMed Web of Science ®Google Scholar

Solomon SR, Solh M, Zhang X, et al. Fludarabine and total-body irradiation conditioning before ablative haploidentical transplantation: long-term safety and efficacy. Biol Blood Marrow Transplant. 2019;25(11):2211–2216. doi:10.1016/j.bbmt.2019.06.017

 PubMed Web of Science ®Google Scholar

Chiusolo P, Bug G, Olivieri A, et al. A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study. Biol Blood Marrow Transplant. 2018;24(6):1243–1249. doi:10.1016/j.bbmt.2018.01.031

 PubMed Web of Science ®Google Scholar

Sugita J, Kagaya Y, Miyamoto T, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2019;54(3):432–441. doi:10.1038/s41409-018-0279-1

 PubMed Web of Science ®Google Scholar

Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4(16):3913–3925. doi:10.1182/bloodadvances.2020001648

 PubMed Web of Science ®Google Scholar

Cieri N, Greco R, Crucitti L, et al. Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant. 2015;21(8):1506–1514. doi:10.1016/j.bbmt.2015.04.025

 PubMed Web of Science ®Google Scholar

Dholaria B, Labopin M, Angelucci E, et al. Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. Am J Hematol. 2020;95(10):1200–1208. doi:10.1002/ajh.25934

 PubMed Web of Science ®Google Scholar

Dholaria B, Labopin M, Angelucci E, et al. Improved outcomes of haploidentical hematopoietic cell transplantation with total body irradiation-based myeloablative conditioning in acute lymphoblastic leukemia. Transplant Cell Ther. 2021;27(2):171 e171–171 e178. doi:10.1016/j.jtct.2020.10.008

 Google Scholar

Swoboda R, Labopin M, Giebel S, et al. Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2022;57(3):399–406. doi:10.1038/s41409-021-01550-0

 PubMed Web of Science ®Google Scholar

Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005

 PubMed Web of Science ®Google Scholar

Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279–1287. doi:10.1016/j.bbmt.2008.08.014

 PubMed Web of Science ®Google Scholar

Kasamon YL, Bolanos-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33(28):3152–3161. doi:10.1200/JCO.2014.60.4777

 PubMed Web of Science ®Google Scholar

Brammer JE, Khouri I, Gaballa S, et al. Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning. Biol Blood Marrow Transplant. 2016;22(3):493–498. doi:10.1016/j.bbmt.2015.10.015

 PubMedGoogle Scholar

Ciurea SO, Shah MV, Saliba RM, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018;24(6):1232–1236. doi:10.1016/j.bbmt.2017.09.005

 PubMed Web of Science ®Google Scholar

Castagna L, Dodero A, Patriarca F, et al. Multicenter phase II study on haploidentical bone marrow transplantation using a reduced-intensity conditioning regimen and posttransplantation cyclophosphamide in patients with poor-prognosis lymphomas. Transplant Cell Ther. 2021;27(4):328 e321–328 e326. doi:10.1016/j.jtct.2021.01.007

 Google Scholar

Tanaka T, Nakamae H, Ito A, et al. A Phase I/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia/lymphoma. Transplant Cell Ther. 2021;27(11):928 e921–928 e927. doi:10.1016/j.jtct.2021.07.010

 Google Scholar

Devillier R, Galimard JE, Labopin M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022;57(9):1421–1427. doi:10.1038/s41409-022-01674-x

 PubMed Web of Science ®Google Scholar

Al Malki MM, Palmer J, Tsai NC, et al. Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Adv. 2022;6(14):4098–4106. doi:10.1182/bloodadvances.2022007264

 PubMed Web of Science ®Google Scholar

Huselton E, Slade M, Trinkaus KM, et al. Propensity score analysis of conditioning intensity in peripheral blood haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(10):2047–2055. doi:10.1016/j.bbmt.2018.05.024

 PubMed Web of Science ®Google Scholar

Modi D, Kim S, Deol A, et al. Comparison of myeloablative and reduced intensity conditioning regimens in haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021;56(3):741–744. doi:10.1038/s41409-020-01079-8

 PubMed Web of Science ®Google Scholar

Solomon SR, St Martin A, Shah NN, et al. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv. 2019;3(19):2836–2844. doi:10.1182/bloodadvances.2019000627

 PubMed Web of Science ®Google Scholar

Santoro N, Labopin M, Ciceri F, et al. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. Cancer. 2019;125(9):1499–1506. doi:10.1002/cncr.31941

 PubMed Web of Science ®Google Scholar